Colorectal cancer - Chemotherapy

Chemotherapy in Colorectal Cancer Introduction Chemotherapy plays a selective but critical role in colorectal cancer treatment. Unlike surgery, which is effective for localized disease, chemotherapy becomes essential when cancer has spread to lymph nodes or distant organs. Understanding which patients benefit from chemotherapy—and which do not—is central to treatment planning. This section covers the role of chemotherapy by disease stage, the agents commonly used, standard treatment regimens, and targeted biological therapies that enhance chemotherapy effectiveness. Role of Chemotherapy by Disease Stage The decision to offer chemotherapy depends heavily on disease stage and specific tumor characteristics. This principle is important because it avoids unnecessary treatment while ensuring at-risk patients receive proven therapies. Stage I colorectal cancer requires no chemotherapy. Surgery alone is curative for these early, localized tumors, making adjuvant chemotherapy unnecessary. Stage II colorectal cancer generally does not receive chemotherapy either, unless high-risk features are present. These high-risk features include tumor perforation, undifferentiated (poorly differentiated) histology, vascular invasion, perineural invasion, or inadequate lymph-node sampling during surgery. When these concerning features exist, the cancer's aggressive behavior justifies chemotherapy despite not having spread to lymph nodes. An important exception exists for patients with mismatch-repair gene abnormalities (also called microsatellite instability-high tumors). These patients do not benefit from standard chemotherapy, so treatment is withheld even if other high-risk features are present. This reflects a fundamental difference in how these tumors respond to chemotherapy drugs. Stage III and Stage IV colorectal cancer are the clear indications for chemotherapy. At these stages, cancer has either spread to lymph nodes (stage III) or to distant organs like the liver or lungs (stage IV). Adding chemotherapy agents—fluorouracil, capecitabine, or oxaliplatin—to surgical treatment significantly improves life expectancy. This makes chemotherapy an integral part of treatment strategy, not optional. Common Chemotherapy Agents Several chemotherapy drugs form the backbone of colorectal cancer regimens. Understanding each agent's properties helps explain why they're combined in specific ways. Fluorouracil (5-FU) is the cornerstone of colorectal cancer chemotherapy. It's administered intravenously and works by inhibiting thymidylate synthase, an enzyme essential for DNA synthesis. This mechanism makes it particularly effective against rapidly dividing cancer cells. Capecitabine is an oral alternative to fluorouracil. It's a pro-drug, meaning the body converts it into fluorouracil in the bloodstream. The advantage of capecitabine is that patients can take it by mouth instead of receiving intravenous infusions, improving convenience. However, it still delivers fluorouracil, so it has similar effectiveness to IV fluorouracil. Oxaliplatin is a platinum-based compound (similar in concept to cisplatin, used in other cancers). It works through a different mechanism—it causes DNA cross-linking, preventing the cancer cell from replicating its genetic material. Importantly, oxaliplatin adds a cumulative side effect called peripheral neuropathy (nerve damage in the hands and feet) that increases with total dose. Irinotecan is a topoisomerase I inhibitor. Topoisomerases are enzymes that cut and reseal DNA strands during replication. By inhibiting topoisomerase I, irinotecan prevents this normal process, leading to cancer cell death. It causes a different toxicity profile than the other agents, particularly affecting the gastrointestinal tract. Standard Chemotherapy Regimens Rather than using single agents, colorectal cancer treatment typically combines multiple chemotherapy drugs. These combinations are given names that serve as shorthand in clinical practice. FOLFOX is arguably the most commonly used first-line regimen. It combines: Folinic acid (leucovorin), which enhances fluorouracil activity Fluorouracil Oxaliplatin This combination is particularly effective for stage III and IV disease, especially when oxaliplatin's ability to kill cancer cells justifies accepting the risk of peripheral neuropathy. CAPOX is an alternative first-line regimen that substitutes capecitabine for intravenous fluorouracil: Capecitabine Oxaliplatin CAPOX offers the convenience of oral capecitabine while maintaining oxaliplatin's effectiveness. It may be preferred for patients who struggle with IV access or prefer oral medications. FOLFIRI combines folinic acid, fluorouracil, and irinotecan. This regimen is typically reserved for second-line therapy (when first-line regimens like FOLFOX have been completed or failed) because irinotecan has different toxicities that may be better tolerated after initial chemotherapy. FOLFOXIRI is the most intensive regimen, combining all four drugs: folinic acid, fluorouracil, oxaliplatin, and irinotecan. This three-drug combination is reserved for selected patients with stage IV disease who can tolerate higher toxicity in exchange for greater anti-cancer effect. It's not standard first-line therapy due to its intensity. A helpful way to remember these regimens: FOLF- indicates the folinic acid and fluorouracil backbone that's nearly universal, while the suffix tells you what else is added (OX for oxaliplatin, IRI for irinotecan, or OXIRI for both). Targeted Biological Therapies Chemotherapy works by killing rapidly dividing cells, but it's nonspecific—it damages cancer cells and some normal cells. Targeted biological therapies work differently: they target specific molecular features of cancer cells, often with greater specificity and potentially fewer side effects. These agents are increasingly added to chemotherapy regimens. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). Cancer cells produce VEGF to trigger new blood vessel formation, supplying the tumor with oxygen and nutrients. By blocking VEGF, bevacizumab starves the tumor. It's frequently added to first-line chemotherapy regimens (FOLFOX or CAPOX) for metastatic disease, improving both progression-free and overall survival. Aflibercept is an anti-VEGF receptor fusion protein with a similar mechanism to bevacizumab—it blocks the VEGF signaling pathway. It's approved specifically for second-line therapy, used after first-line chemotherapy has failed or progressed. Cetuximab and panitumumab target the epidermal growth factor receptor (EGFR), a different pathway than VEGF. EGFR stimulates cancer cell growth and survival, so blocking it slows tumor progression. Both are monoclonal antibodies approved for second-line therapy. An important caveat: these EGFR inhibitors only work effectively in tumors that lack mutations in the KRAS gene. Tumors with KRAS mutations will not respond to anti-EGFR therapy, making molecular testing essential before treatment. The distinction between first-line and second-line targeted therapies reflects clinical trial evidence: bevacizumab has proven benefit when added to initial chemotherapy, while aflibercept, cetuximab, and panitumumab have been validated as second-line options for patients whose disease progresses despite first-line treatment. Surgical Approaches and Adjuvant Treatment While this section focuses on chemotherapy, understanding how it integrates with surgery is important. Early rectal cancer can be treated with either local excision (removing the tumor through the rectoscope without full surgical resection) or radical surgery (removing a portion of the bowel). The choice depends on tumor stage and risk factors. Neoadjuvant therapy (chemotherapy or radiotherapy given before surgery) or adjuvant therapy (given after surgery) may accompany surgery depending on stage. Adjuvant chemotherapy and radiotherapy are standard for stage III and high-risk stage II colorectal cancer. For rectal cancer specifically, radiotherapy may be added to chemotherapy for stage III disease to reduce local recurrence risk. This multimodal approach—combining surgery, chemotherapy, and sometimes radiotherapy—maximizes cure rates for advanced colorectal cancers.